FDA’s new warning about GLP-1s and blindness explained
Katherine Langford
Katherine Langford
Editor-in-Chief · Edina, MN
Katherine oversees editorial operations across all six brands. Before joining The Meridan Group, she spent 14 years at the Minneapolis Star Tribune, where she led the metro desk through its digital transformation. She holds a Master's in Journalism from Northwestern's Medill School.
More from Katherine →Editor-in-Chief · Friday, November 13, 2026 at 8:16 PM · 1 min read
“The FDA is making this warning out of an abundance of caution" | Doctors still aren’t sure how these drugs could have this effect on the body.